AKT1 and colitis: These findings identify a novel mechanism by which Akkermansia-centered FMT inhibits the PI3K-Akt signaling pathway and MAPK signaling pathway via bacterial metabolites (butyric acid, deoxycholic acid) to treat C. jejuni infection in the host organism and alleviate colitis(Figure 8).